25.76
+0.32(+1.26%)
Currency In USD
| Previous Close | 25.44 |
| Open | 25.53 |
| Day High | 26.24 |
| Day Low | 25.3 |
| 52-Week High | 26.24 |
| 52-Week Low | 7.75 |
| Volume | 102,138 |
| Average Volume | 51,146 |
| Market Cap | 197.64M |
| PE | -4.63 |
| EPS | -5.56 |
| Moving Average 50 Days | 18.8 |
| Moving Average 200 Days | 14.86 |
| Change | 0.32 |
If you invested $1000 in Assembly Biosciences, Inc. (ASMB) 10 years ago, it would be worth $157.26 as of August 18, 2025 at a share price of $25.76. Whereas If you bought $1000 worth of Assembly Biosciences, Inc. (ASMB) shares 5 years ago, it would be worth $98.97 as of August 18, 2025 at a share price of $25.76.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
GlobeNewswire Inc.
Aug 08, 2025 12:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of a
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
GlobeNewswire Inc.
Aug 08, 2025 12:00 PM GMT
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in ge
Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
GlobeNewswire Inc.
Aug 06, 2025 8:05 PM GMT
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Furth